Ceralasertib is under clinical development by AstraZeneca and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ceralasertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ceralasertib overview

Ceralasertib is under development for the treatment of head and neck cancer squamous cell carcinoma, metastatic triple negative breast cancer, HER-2 negative breast cancer, non-small cell lung cancer, metastatic melanoma, advanced biliary tract cancer, endometrial cancer, cervical cancer, uterine cancer, small cell lung cancer, chronic myelomonocytic leukemia, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, metastatic colorectal cancer, salivary gland cancer, myelodysplastic syndrome, homologous-recombination deficient (HRD) of adenocarcinoma of the gastroesophageal junction, non-hodgkin's lymphoma, ovarian cancer, peritoneal cancer, fallopian tube cancer, refractory solid tumors including lung adenocarcinoma, metastatic renal cell carcinoma, urothelial cell carcinoma, pancreatic ductal adenocarcinoma, other solid tumors. The drug candidate is administered through oral route in the form of film coated tablet and gelatin coated capsule. It targets ataxia telangiectasia and rad3 related (ATR) kinase.

It was also under development for the treatment of prolymphocytic leukemia (PLL), Burkitt lymphoma, acute lymphocytic leukemia, hairy cell leukemia (HCL), relapsed/refractory chronic lymphocytic leukemia (CLL), indolent  b-cell lymphoma and B cell lymphomas.

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

For a complete picture of Ceralasertib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.